UniProt ID | NCK1_HUMAN | |
---|---|---|
UniProt AC | P16333 | |
Protein Name | Cytoplasmic protein NCK1 | |
Gene Name | NCK1 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 377 | |
Subcellular Localization | Cytoplasm. Endoplasmic reticulum. Nucleus. Mostly cytoplasmic, but shuttles between the cytoplasm and the nucleus. Import into the nucleus requires the interaction with SOCS7. Predominantly nuclear following genotoxic stresses, such as UV irradiation | |
Protein Description | Adapter protein which associates with tyrosine-phosphorylated growth factor receptors, such as KDR and PDGFRB, or their cellular substrates. Maintains low levels of EIF2S1 phosphorylation by promoting its dephosphorylation by PP1. Plays a role in the DNA damage response, not in the detection of the damage by ATM/ATR, but for efficient activation of downstream effectors, such as that of CHEK2. Plays a role in ELK1-dependent transcriptional activation in response to activated Ras signaling. Modulates the activation of EIF2AK2/PKR by dsRNA. May play a role in cell adhesion and migration through interaction with ephrin receptors.. | |
Protein Sequence | MAEEVVVVAKFDYVAQQEQELDIKKNERLWLLDDSKSWWRVRNSMNKTGFVPSNYVERKNSARKASIVKNLKDTLGIGKVKRKPSVPDSASPADDSFVDPGERLYDLNMPAYVKFNYMAEREDELSLIKGTKVIVMEKCSDGWWRGSYNGQVGWFPSNYVTEEGDSPLGDHVGSLSEKLAAVVNNLNTGQVLHVVQALYPFSSSNDEELNFEKGDVMDVIEKPENDPEWWKCRKINGMVGLVPKNYVTVMQNNPLTSGLEPSPPQCDYIRPSLTGKFAGNPWYYGKVTRHQAEMALNERGHEGDFLIRDSESSPNDFSVSLKAQGKNKHFKVQLKETVYCIGQRKFSTMEELVEHYKKAPIFTSEQGEKLYLVKHLS | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Acetylation | ------MAEEVVVVA ------CCCEEEEEE | 22.96 | 22223895 | |
12 (in isoform 2) | Phosphorylation | - | 35.97 | 23909892 | |
13 | Phosphorylation | VVVAKFDYVAQQEQE EEEEECCEECCCCEE | 10.79 | - | |
21 (in isoform 2) | Phosphorylation | - | 9.13 | 25159151 | |
25 (in isoform 2) | Phosphorylation | - | 65.46 | 25159151 | |
27 (in isoform 2) | Phosphorylation | - | 59.01 | 29507054 | |
48 | Phosphorylation | VRNSMNKTGFVPSNY HCCCCCCCCCCCHHH | 30.74 | 23882029 | |
53 | Phosphorylation | NKTGFVPSNYVERKN CCCCCCCHHHHHHCC | 35.18 | 23882029 | |
55 | Phosphorylation | TGFVPSNYVERKNSA CCCCCHHHHHHCCCH | 14.18 | 26074081 | |
61 | Phosphorylation | NYVERKNSARKASIV HHHHHCCCHHHHHHH | 32.27 | 26074081 | |
66 | Phosphorylation | KNSARKASIVKNLKD CCCHHHHHHHHHHHH | 30.83 | 29514088 | |
69 | Ubiquitination | ARKASIVKNLKDTLG HHHHHHHHHHHHHHC | 55.69 | - | |
74 | Phosphorylation | IVKNLKDTLGIGKVK HHHHHHHHHCCCCCC | 25.87 | 18212344 | |
79 | Acetylation | KDTLGIGKVKRKPSV HHHHCCCCCCCCCCC | 42.54 | 25953088 | |
79 | Ubiquitination | KDTLGIGKVKRKPSV HHHHCCCCCCCCCCC | 42.54 | - | |
85 | Phosphorylation | GKVKRKPSVPDSASP CCCCCCCCCCCCCCC | 49.68 | 29255136 | |
89 | Phosphorylation | RKPSVPDSASPADDS CCCCCCCCCCCCCCC | 25.28 | 29255136 | |
91 | Phosphorylation | PSVPDSASPADDSFV CCCCCCCCCCCCCCC | 25.27 | 29255136 | |
96 | Phosphorylation | SASPADDSFVDPGER CCCCCCCCCCCCCCC | 27.93 | 21945579 | |
105 | Phosphorylation | VDPGERLYDLNMPAY CCCCCCCCCCCCCEE | 25.30 | 25159151 | |
109 | Sulfoxidation | ERLYDLNMPAYVKFN CCCCCCCCCEEEEEE | 2.33 | 31801345 | |
112 | Phosphorylation | YDLNMPAYVKFNYMA CCCCCCEEEEEEECC | 9.78 | 21945579 | |
117 | Phosphorylation | PAYVKFNYMAEREDE CEEEEEEECCCCCCH | 10.80 | 26074081 | |
126 | Phosphorylation | AEREDELSLIKGTKV CCCCCHHHCCCCCEE | 26.46 | 26074081 | |
129 | Ubiquitination | EDELSLIKGTKVIVM CCHHHCCCCCEEEEE | 66.86 | - | |
131 | Phosphorylation | ELSLIKGTKVIVMEK HHHCCCCCEEEEEEE | 19.69 | 26074081 | |
147 | Phosphorylation | SDGWWRGSYNGQVGW CCCEEECCCCCCEEE | 13.57 | 23663014 | |
148 | Phosphorylation | DGWWRGSYNGQVGWF CCEEECCCCCCEEEE | 26.57 | 26074081 | |
157 | Phosphorylation | GQVGWFPSNYVTEEG CCEEEECHHHCCCCC | 31.17 | 28450419 | |
159 | Phosphorylation | VGWFPSNYVTEEGDS EEEECHHHCCCCCCC | 17.06 | 28450419 | |
161 | Phosphorylation | WFPSNYVTEEGDSPL EECHHHCCCCCCCCC | 20.26 | 28787133 | |
166 | Phosphorylation | YVTEEGDSPLGDHVG HCCCCCCCCCHHHHC | 32.64 | 25159151 | |
174 | Phosphorylation | PLGDHVGSLSEKLAA CCHHHHCCHHHHHHH | 27.86 | 28787133 | |
176 | Phosphorylation | GDHVGSLSEKLAAVV HHHHCCHHHHHHHHH | 34.09 | 28450419 | |
178 | Ubiquitination | HVGSLSEKLAAVVNN HHCCHHHHHHHHHHC | 39.80 | - | |
202 | Phosphorylation | VQALYPFSSSNDEEL EEECCCCCCCCCCCC | 28.49 | 27251275 | |
203 | Phosphorylation | QALYPFSSSNDEELN EECCCCCCCCCCCCC | 33.27 | 27251275 | |
204 | Phosphorylation | ALYPFSSSNDEELNF ECCCCCCCCCCCCCC | 47.29 | 27251275 | |
231 | Ubiquitination | ENDPEWWKCRKINGM CCCHHHHHEEEECCE | 25.82 | - | |
246 | Phosphorylation | VGLVPKNYVTVMQNN EEECCCCEEEEEECC | 12.01 | 20068231 | |
248 | Phosphorylation | LVPKNYVTVMQNNPL ECCCCEEEEEECCCC | 10.41 | 27251275 | |
256 | Phosphorylation | VMQNNPLTSGLEPSP EEECCCCCCCCCCCC | 23.23 | 20068231 | |
257 | Phosphorylation | MQNNPLTSGLEPSPP EECCCCCCCCCCCCC | 49.41 | 29978859 | |
262 | Phosphorylation | LTSGLEPSPPQCDYI CCCCCCCCCCCCCCC | 39.58 | 23403867 | |
268 | Phosphorylation | PSPPQCDYIRPSLTG CCCCCCCCCCHHHCC | 13.37 | 20068231 | |
272 | Phosphorylation | QCDYIRPSLTGKFAG CCCCCCHHHCCCCCC | 28.81 | 23403867 | |
274 | Phosphorylation | DYIRPSLTGKFAGNP CCCCHHHCCCCCCCC | 42.54 | 29978859 | |
286 | Ubiquitination | GNPWYYGKVTRHQAE CCCCCCCEEEHHHHH | 25.06 | - | |
310 | Phosphorylation | GDFLIRDSESSPNDF CCEEEECCCCCCCCE | 29.54 | 27251275 | |
312 | Phosphorylation | FLIRDSESSPNDFSV EEEECCCCCCCCEEE | 55.86 | 20068231 | |
313 | Phosphorylation | LIRDSESSPNDFSVS EEECCCCCCCCEEEE | 24.54 | 25159151 | |
318 | Phosphorylation | ESSPNDFSVSLKAQG CCCCCCEEEEEEECC | 17.41 | 28857561 | |
322 | Ubiquitination | NDFSVSLKAQGKNKH CCEEEEEEECCCCCC | 31.02 | - | |
339 | Phosphorylation | VQLKETVYCIGQRKF EEEEEEEEEEECCCC | 5.93 | 25839225 | |
345 | Ubiquitination | VYCIGQRKFSTMEEL EEEEECCCCCCHHHH | 35.46 | - | |
347 | Phosphorylation | CIGQRKFSTMEELVE EEECCCCCCHHHHHH | 29.85 | 28450419 | |
348 | Phosphorylation | IGQRKFSTMEELVEH EECCCCCCHHHHHHH | 31.56 | 28450419 | |
357 | Ubiquitination | EELVEHYKKAPIFTS HHHHHHHHHCCEEEC | 44.35 | - | |
358 | Ubiquitination | ELVEHYKKAPIFTSE HHHHHHHHCCEEECC | 52.83 | - | |
364 | Phosphorylation | KKAPIFTSEQGEKLY HHCCEEECCCCCEEE | 19.71 | 29496907 | |
369 | Ubiquitination | FTSEQGEKLYLVKHL EECCCCCEEEEEEEC | 49.62 | - |
Modified Location | Modified Residue | Modification | Type of Upstream Proteins | Gene Name of Upstream Proteins | UniProt AC of Upstream Proteins | Sources |
---|---|---|---|---|---|---|
105 | Y | Phosphorylation | Kinase | ABL1 | P00519 | GPS |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of NCK1_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of NCK1_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND MASS SPECTROMETRY. | |
Phosphorylation | |
Reference | PubMed |
"Quantitative phosphoproteomic analysis of T cell receptor signalingreveals system-wide modulation of protein-protein interactions."; Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,Rodionov V., Han D.K.; Sci. Signal. 2:RA46-RA46(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-85; SER-96 AND TYR-105,AND MASS SPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-85; SER-91 AND SER-96,AND MASS SPECTROMETRY. | |
"Global proteomic profiling of phosphopeptides using electron transferdissociation tandem mass spectrometry."; Molina H., Horn D.M., Tang N., Mathivanan S., Pandey A.; Proc. Natl. Acad. Sci. U.S.A. 104:2199-2204(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-85; SER-96 AND TYR-105,AND MASS SPECTROMETRY. | |
"An extensive survey of tyrosine phosphorylation revealing new sitesin human mammary epithelial cells."; Heibeck T.H., Ding S.-J., Opresko L.K., Zhao R., Schepmoes A.A.,Yang F., Tolmachev A.V., Monroe M.E., Camp D.G. II, Smith R.D.,Wiley H.S., Qian W.-J.; J. Proteome Res. 8:3852-3861(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-105, AND MASSSPECTROMETRY. | |
"Phosphoproteome of resting human platelets."; Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,Schuetz C., Walter U., Gambaryan S., Sickmann A.; J. Proteome Res. 7:526-534(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-105, AND MASSSPECTROMETRY. | |
"Multiple reaction monitoring for robust quantitative proteomicanalysis of cellular signaling networks."; Wolf-Yadlin A., Hautaniemi S., Lauffenburger D.A., White F.M.; Proc. Natl. Acad. Sci. U.S.A. 104:5860-5865(2007). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-105, AND MASSSPECTROMETRY. | |
"Time-resolved mass spectrometry of tyrosine phosphorylation sites inthe epidermal growth factor receptor signaling network reveals dynamicmodules."; Zhang Y., Wolf-Yadlin A., Ross P.L., Pappin D.J., Rush J.,Lauffenburger D.A., White F.M.; Mol. Cell. Proteomics 4:1240-1250(2005). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT TYR-105, AND MASSSPECTROMETRY. |